183 related articles for article (PubMed ID: 22544559)
41. Metabolic tumor width parameters as determined on PET/CT predict disease-free survival and treatment response in squamous cell carcinoma of the esophagus.
Roedl JB; Halpern EF; Colen RR; Sahani DV; Fischman AJ; Blake MA
Mol Imaging Biol; 2009; 11(1):54-60. PubMed ID: 18769974
[TBL] [Abstract][Full Text] [Related]
42. Irreversible multitargeted ErbB family inhibitors for therapy of lung and breast cancer.
Subramaniam D; He AR; Hwang J; Deeken J; Pishvaian M; Hartley ML; Marshall JL
Curr Cancer Drug Targets; 2015; 14(9):775-93. PubMed ID: 25435079
[TBL] [Abstract][Full Text] [Related]
43. Multimodality therapy for esophageal cancer.
Krasna MJ
Oncology (Williston Park); 2010 Nov; 24(12):1134-8. PubMed ID: 21141694
[TBL] [Abstract][Full Text] [Related]
44. Esophageal Adenocarcinoma Cells and Xenograft Tumors Exposed to Erb-b2 Receptor Tyrosine Kinase 2 and 3 Inhibitors Activate Transforming Growth Factor Beta Signaling, Which Induces Epithelial to Mesenchymal Transition.
Ebbing EA; Steins A; Fessler E; Stathi P; Lesterhuis WJ; Krishnadath KK; Vermeulen L; Medema JP; Bijlsma MF; van Laarhoven HWM
Gastroenterology; 2017 Jul; 153(1):63-76.e14. PubMed ID: 28286209
[TBL] [Abstract][Full Text] [Related]
45. Comparative study between endoscopic ultrasonography and positron emission tomography-computed tomography in staging patients with esophageal squamous cell carcinoma.
Yen TJ; Chung CS; Wu YW; Yen RF; Cheng MF; Lee JM; Hsu CH; Chang YL; Wang HP
Dis Esophagus; 2012 Jan; 25(1):40-7. PubMed ID: 21595776
[TBL] [Abstract][Full Text] [Related]
46. Preoperative therapy in esophageal cancer.
Ku GY; Ilson DH
Clin Adv Hematol Oncol; 2008 May; 6(5):371-9. PubMed ID: 18516027
[TBL] [Abstract][Full Text] [Related]
47. Esophageal cancer: the role of integrated CT-PET in initial staging and response assessment after preoperative therapy.
Munden RF; Macapinlac HA; Erasmus JJ
J Thorac Imaging; 2006 May; 21(2):137-45. PubMed ID: 16770230
[TBL] [Abstract][Full Text] [Related]
48. Utility of
Arnett ALH; Merrell KW; Macintosh EM; James SE; Nathan MA; Shen KR; Ravi K; Neben Wittich MA; Haddock MG; Hallemeier CL
J Thorac Oncol; 2017 Jan; 12(1):121-128. PubMed ID: 27569732
[TBL] [Abstract][Full Text] [Related]
49. Optimal preoperative neoadjuvant therapy for resectable locally advanced esophageal squamous cell carcinoma.
Leng XF; Daiko H; Han YT; Mao YS
Ann N Y Acad Sci; 2020 Dec; 1482(1):213-224. PubMed ID: 33067818
[TBL] [Abstract][Full Text] [Related]
50. Multidisciplinary Therapy of Esophageal Cancer.
Egyud MR; Tseng JF; Suzuki K
Surg Clin North Am; 2019 Jun; 99(3):419-437. PubMed ID: 31047033
[TBL] [Abstract][Full Text] [Related]
51. Long-term outcome of a phase II study of docetaxel-based multimodality chemoradiotherapy for locally advanced carcinoma of the esophagus or gastroesophageal junction.
Choong NW; Mauer AM; Haraf DC; Ferguson MK; Sandler AB; Kesler KA; Fishkin PA; Ansari RH; Wade J; Krauss SA; Sciortino DF; Posner MC; Kocherginsky M; Hoffman PC; Szeto L; Vokes EE
Med Oncol; 2011 Dec; 28 Suppl 1():S152-61. PubMed ID: 20730572
[TBL] [Abstract][Full Text] [Related]
52. Clinical staging of patients with early esophageal adenocarcinoma: does FDG-PET/CT have a role?
Cuellar SL; Carter BW; Macapinlac HA; Ajani JA; Komaki R; Welsh JW; Lee JH; Swisher SG; Correa AM; Erasmus JJ; Hofstetter WL
J Thorac Oncol; 2014 Aug; 9(8):1202-6. PubMed ID: 25157774
[TBL] [Abstract][Full Text] [Related]
53. Predictive value of initial PET-SUVmax in patients with locally advanced esophageal and gastroesophageal junction adenocarcinoma.
Rizk NP; Tang L; Adusumilli PS; Bains MS; Akhurst TJ; Ilson D; Goodman K; Rusch VW
J Thorac Oncol; 2009 Jul; 4(7):875-9. PubMed ID: 19487968
[TBL] [Abstract][Full Text] [Related]
54. Value of complete metabolic response by (18)F-fluorodeoxyglucose-positron emission tomography in oesophageal cancer for prediction of pathologic response and survival after preoperative chemoradiotherapy.
Kim MK; Ryu JS; Kim SB; Ahn JH; Kim SY; Park SI; Kim YH; Song HY; Shin JH; Jung HY; Lee GH; Choi KD; Cho KJ; Kim JH
Eur J Cancer; 2007 Jun; 43(9):1385-91. PubMed ID: 17512192
[TBL] [Abstract][Full Text] [Related]
55. Management of Locally Advanced Gastroesophageal Cancer: Still a Multidisciplinary Global Challenge?
Al-Batran SE; Lorenzen S
Hematol Oncol Clin North Am; 2017 Jun; 31(3):441-452. PubMed ID: 28501086
[TBL] [Abstract][Full Text] [Related]
56. Correlation of molecular response as measured by 18-FDG positron emission tomography with outcome after chemoradiotherapy in patients with esophageal carcinoma.
Konski AA; Cheng JD; Goldberg M; Li T; Maurer A; Yu JQ; Haluszka O; Scott W; Meropol NJ; Cohen SJ; Freedman G; Weiner LM
Int J Radiat Oncol Biol Phys; 2007 Oct; 69(2):358-63. PubMed ID: 17532577
[TBL] [Abstract][Full Text] [Related]
57. Assessment of Response to Neoadjuvant Chemoradiotherapy by 18F-FDG PET/CT in Patients With Locally Advanced Esophagogastric Junction Adenocarcinoma.
Sánchez-Izquierdo N; Perlaza P; Pagès M; Buxó E; Rios J; Rubello D; Colletti PM; Mayoral M; Casanueva S; Fernández-Esparrach G; Ginés A; Fuster D
Clin Nucl Med; 2020 Jan; 45(1):38-43. PubMed ID: 31714278
[TBL] [Abstract][Full Text] [Related]
58. MAHOGANY: margetuximab combination in HER2+ unresectable/metastatic gastric/gastroesophageal junction adenocarcinoma.
Catenacci DV; Rosales M; Chung HC; H Yoon H; Shen L; Moehler M; Kang YK
Future Oncol; 2021 Apr; 17(10):1155-1164. PubMed ID: 33263418
[TBL] [Abstract][Full Text] [Related]
59. Case records of the Massachusetts General Hospital. Case 19-2009. A 63-year-old woman with carcinoma of the gastroesophageal junction.
Kwak EL; Hong TS; Berger DL; Forcione DG; Uppot RN; Lauwers GY
N Engl J Med; 2009 Jun; 360(25):2656-64. PubMed ID: 19535805
[No Abstract] [Full Text] [Related]
60. Analysis of pathological complete response rates with paclitaxel-based regimens in trimodality therapy for esophageal cancer.
Boggs DH; Tarabolous C; Morris CG; Hanna A; Burrows W; Horiba N; Suntharalingam M
Dis Esophagus; 2015 Oct; 28(7):619-25. PubMed ID: 24863682
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
